Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2025 09:00 ET | Source: Femasys Inc.

Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe

--Marks key milestone in European commercialization strategy under EU Medical Device Regulation (MDR)-- ATLANTA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical...
October 16, 2025 09:00 ET | Source: Femasys Inc.

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

SAN ANTONIO, Texas, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and...
September 22, 2025 09:00 ET | Source: Femasys Inc.

Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed

ATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...
September 11, 2025 09:00 ET | Source: Femasys Inc.

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

ATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...
September 08, 2025 09:00 ET | Source: Femasys Inc.

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

ATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...
August 20, 2025 09:00 ET | Source: Femasys Inc.

Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control

--Advances European commercialization strategy following CE mark approval-- ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making...
August 06, 2025 09:00 ET | Source: Femasys Inc.

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

--Initiation of access to FemBloc, a revolutionary non-surgical permanent contraceptive, as global availability accelerates-- ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY),...
June 17, 2025 09:00 ET | Source: Femasys Inc.

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

--New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE)...
March 27, 2025 09:00 ET | Source: Femasys Inc.

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

-- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025...
March 19, 2025 09:20 ET | Source: Femasys Inc.

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

ATLANTA, March 19, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of...